NCT04943614

Biodex Balance System Training in Diabetic Neuropathy

Completed NA Last updated 15 December 2021

What this trial tests

NA trial testing Biodex balance system in Diabetic Neuropathies in 88 participants. Completed in 27 August 2021.

Timeline

1 December 2020

Primary endpoint
27 August 2021

27 August 2021

Quick facts

Lead sponsor	Riphah International University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	88
Start date	1 December 2020
Primary completion	27 August 2021
Estimated completion	27 August 2021
Sites	1 location across Pakistan

Drugs / interventions tested

• Biodex balance system
• conventional exercises

Conditions studied

• Diabetic Neuropathies — all drugs for Diabetic Neuropathies →

Sponsor

Riphah International University

Who can join

Adults 40 to 70, any sex, with Diabetic Neuropathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Type II-diabetic neuropathy is the most common and correlated problem with diabetes that deteriorates with the passage of time. Balance disorders are also resulting of movement strategy damage, biomechanical and mechanical disorientation. The balance disorder has been reported to be related to abnormal somatosensory feedback, which is utilized in the development of an interior depiction of body motion and position (inner model) in the central nervous system. The Biodex stability system offers a system that can deliver particular hip and ankle postural training strategy with external biofeedback as a monitor to enhance the reduced subclinical limitations of patients with diabetic neuropathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.